Overview
This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera
Eligibility
Inclusion Criteria:
- Confirmed diagnosis of PV according to either the 2008 or 2016 WHO classification criteria
- PV patients being only treated with phlebotomy and the interval is 4-9 weeks
Exclusion Criteria:
- Patients administrated drugs for PV treatment such as hydroxyurea or ruxolitinib (aspirin is excluded)